JOHNS HOPKINS UNIVERSITY
๐ณ๐ฆNamibia
- Country
- ๐ณ๐ฆNamibia
- Ownership
- -
- Established
- 1876-01-01
- Employees
- 19.4K
- Market Cap
- -
- Website
- https://www.jhu.edu/
Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics. - 1
Phase 3
Completed
- Conditions
- Substance-Related Disorders
- First Posted Date
- 2002-04-08
- Last Posted Date
- 2017-01-12
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 390
- Registration Number
- NCT00033020
- Locations
- ๐บ๐ธ
Aegis Medical Systems, Inc., Bakersfield, California, United States
๐บ๐ธOasis Clinic, Washington, District of Columbia, United States
๐บ๐ธGlenwood Life Counseling Center, Baltimore, Maryland, United States
Intraventricular Rt-PA in Patients With Intraventricular Hemorrhage
Phase 2
Completed
- Conditions
- Cerebral Hemorrhage
- First Posted Date
- 2002-01-11
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 30
- Registration Number
- NCT00029315
- Locations
- ๐บ๐ธ
The Johns Hopkins University, Baltimore, Maryland, United States
Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome
Not Applicable
Completed
- Conditions
- Systemic Lupus ErythematosusAntiphospholipid Antibody Syndrome
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 35
- Registration Number
- NCT00010400
- Locations
- ๐บ๐ธ
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
๐บ๐ธJohns Hopkins University School of Medicine, Baltimore, Maryland, United States
Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus
Phase 2
Completed
- Conditions
- Pemphigus
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2008-10-02
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 35
- Registration Number
- NCT00010413
- Locations
- ๐บ๐ธ
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
Phase 2
Completed
- Conditions
- Anemia, Hemolytic, AutoimmuneFelty SyndromePurpura, ThrombocytopenicAutoimmune Diseases
- First Posted Date
- 2001-02-02
- Last Posted Date
- 2008-09-10
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 32
- Registration Number
- NCT00010387
- Locations
- ๐บ๐ธ
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
The Depression in Alzheimer's Disease Study (DIADS)
Phase 4
Completed
- Conditions
- Alzheimer DiseaseDepression
- First Posted Date
- 2001-01-24
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Johns Hopkins University
- Registration Number
- NCT00009191
- Locations
- ๐บ๐ธ
Johns Hopkins University, Baltimore, Maryland, United States
Psychological Treatments for Scleroderma
Phase 2
Completed
- Conditions
- DepressionSystemic SclerosisPainScleroderma
- Interventions
- Behavioral: Self-help cognitive behavioral intervention facilitated by a psychologistBehavioral: Cognitive behavioral therapyBehavioral: Disease/health education
- First Posted Date
- 2000-12-18
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 89
- Registration Number
- NCT00007267
- Locations
- ๐บ๐ธ
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Naltrexone Treatment for Alcoholism
Phase 4
Completed
- Conditions
- Alcoholism
- First Posted Date
- 1999-11-03
- Last Posted Date
- 2010-05-14
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 192
- Registration Number
- NCT00000438
- Locations
- ๐บ๐ธ
Johns Hopkins Hospital, Baltimore, Maryland, United States
Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis
Not Applicable
Completed
- Conditions
- EpilepsyCysticercosis
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 120
- Registration Number
- NCT00004403
ยฉ Copyright 2025. All Rights Reserved by MedPath